Similar articles

• Indian biogenerics industry emerges.

  Jayaraman KS. Jayaraman KS. Nat Biotechnol. 2003 Oct;21(10):1115-6. doi: 10.1038/nbt882. Nat Biotechnol. 2003. PMID: 14520378 No abstract available.
• Patent threat in emerging economies shifts to biotech.

  Jayaranam K. Jayaranam K. Nat Biotechnol. 2008 May;26(5):481-3. doi: 10.1038/nbt0508-481. Nat Biotechnol. 2008. PMID: 18464760 No abstract available.
• Overcoming the challenges in the pharma/biotech industry.

  Graul AI, Prous JR. Graul AI, et al. Drug News Perspect. 2007 Jan-Feb;20(1):57-68. Drug News Perspect. 2007. PMID: 17332900
• [Similarity of biotechnology-derived drugs: regulatory framework and specificity].

  Prugnaud JL. Prugnaud JL. Ann Pharm Fr. 2008 Aug;66(4):206-11. doi: 10.1016/j.pharma.2008.07.008. Epub 2008 Sep 9. Ann Pharm Fr. 2008. PMID: 18847566 Review. French.
• Three drugs facing key patent expirations and potential generic entry from June 2020 to July 2020.

  Friedman Y. Friedman Y. Pharm Pat Anal. 2020 May;9(3):75-76. doi: 10.4155/ppa-2020-0011. Epub 2020 Jun 16. Pharm Pat Anal. 2020. PMID: 32539666 Review. No abstract available.